At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 280 enrolled
Drug / intervention
PS433540 +2 moredrug
Likely dose
PS433540 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of a Novel Dual Angiotensin and Endothelin Receptor Antagonist (PS433540) in Subjects With Stage I and II Hypertension
In Brief
A Phase 2 clinical trial evaluating PS433540 and placebo for Hypertension. Completed, enrolled 280 participants across 15 sites.
Detailed Summary
The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2007
Primary CompletionApr 2008
Study CompletionMay 2008
TodayJul 2026
First PostedAug 30, 2007
Enrollment StartAug 1, 2007
Primary CompletionApr 1, 2008
Study CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.8 years ago
Interventions
PS433540drug
200mg capsule, once daily for 28 days
placebodrug
placebo capsule, once daily for 28 days
PS433540drug
500mg capsule, once daily for 28 days